Tibet Aim Pharm Inc (002826) — Working Capital to Net Assets Ratio
Tibet Aim Pharm Inc (002826) has a Working Capital to Net Assets ratio of 55.2% as of March 2026. Working capital of CN¥462.81 Million (current assets of CN¥723.27 Million minus current liabilities of CN¥260.46 Million) is measured against net assets of CN¥838.02 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See Tibet Aim Pharm Inc balance sheet quality to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Tibet Aim Pharm Inc Working Capital to Net Assets (2013–2025)
This chart shows how Tibet Aim Pharm Inc's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2013 to 2025. As of March 2026, the ratio stands at 55.2%, reflecting working capital of CN¥462.81 Million against net assets of CN¥838.02 Million CNY. Check 002826 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Tibet Aim Pharm Inc (2013–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Tibet Aim Pharm Inc from 2013 to 2025, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 002826 company net worth.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 53.6% | CN¥437.00 Million | CN¥816.02 Million | CN¥633.68 Million | CN¥196.68 Million | ▲ +6.3 pp |
| 2024 | 47.3% | CN¥352.50 Million | CN¥745.58 Million | CN¥527.61 Million | CN¥175.12 Million | ▲ +4.8 pp |
| 2023 | 42.5% | CN¥318.59 Million | CN¥750.06 Million | CN¥489.67 Million | CN¥171.08 Million | ▲ +0.7 pp |
| 2022 | 41.7% | CN¥313.10 Million | CN¥750.00 Million | CN¥575.01 Million | CN¥261.91 Million | ▲ +5.2 pp |
| 2021 | 36.5% | CN¥262.83 Million | CN¥720.11 Million | CN¥362.17 Million | CN¥99.35 Million | ▲ +2.7 pp |
| 2020 | 33.8% | CN¥231.98 Million | CN¥687.15 Million | CN¥450.25 Million | CN¥218.27 Million | ▼ 0.0 pp |
| 2019 | 33.8% | CN¥220.26 Million | CN¥652.17 Million | CN¥400.57 Million | CN¥180.30 Million | ▼ -19.0 pp |
| 2018 | 52.8% | CN¥326.56 Million | CN¥618.40 Million | CN¥464.22 Million | CN¥137.66 Million | ▼ -5.7 pp |
| 2017 | 58.5% | CN¥353.42 Million | CN¥604.53 Million | CN¥479.56 Million | CN¥126.14 Million | ▼ -6.9 pp |
| 2016 | 65.4% | CN¥363.12 Million | CN¥555.44 Million | CN¥452.01 Million | CN¥88.90 Million | ▲ +24.7 pp |
| 2015 | 40.6% | CN¥100.90 Million | CN¥248.25 Million | CN¥208.40 Million | CN¥107.49 Million | ▲ +1.2 pp |
| 2014 | 39.5% | CN¥70.68 Million | CN¥179.12 Million | CN¥159.72 Million | CN¥89.05 Million | ▲ +44.1 pp |
| 2013 | -4.6% | CN¥-3.30 Million | CN¥71.66 Million | CN¥78.14 Million | CN¥81.43 Million | — |